When is $100 million not $100 million? When it’s a proxy,possibly even something akin to a bet. The nice, round figure is the target initial public offering value for Editas Medicine, and a biotechnology firm with a mission of using gene editing to treat disease. The company has already raised more than $160 million from […]
Source: fivethirtyeight.com